Aurinia Pharmaceuticals (AUPH) Raw Materials (2023 - 2026)

Aurinia Pharmaceuticals has reported Raw Materials for 4 years, with the latest figure at $658000.0 in Q1 2026.

• For the quarter ending Q1 2026, Raw Materials fell 14.66% year-over-year to $658000.0; the trailing twelve-month figure through Mar 2026 stood at $658000.0 (down 14.66% YoY), and the FY2025 full-year result was $658000.0, down 61.34% from the prior year.
• Raw Materials for Q1 2026 stood at $658000.0, roughly flat from $658000.0 in the prior quarter.
• The five-year high for Raw Materials was $1.7 million in Q4 2023, with the low at $658000.0 in Q4 2025.
• Historically, Raw Materials has averaged $1.0 million across 4 years, with a median of $771000.0 in 2025.
• Annual changes were most pronounced in 2024 — Raw Materials fell 2.52% — and 2025, when it sank 61.34%.
• Aurinia Pharmaceuticals' Raw Materials stood at $1.7 million in 2023, then decreased by 2.52% to $1.7 million in 2024, then plunged by 61.34% to $658000.0 in 2025, then changed by 0.0% to $658000.0 in 2026.
• The last three Raw Materials figures came in at $658000.0 (Q1 2026), $658000.0 (Q4 2025), and $771000.0 (Q3 2025), per Business Quant data.